Sitemap Home About Careers Products Research News Contact us Eisai Worldwide Transparency hhc Corporate Philosophy Financial Highlights Compliance Handbook Corporate Responsibility Eisai is one of the world's leading research-based pharmaceutical companies. We define our corporate mission as "giving first thought to patients and their families, and to increasing the benefits health care provides," which we call human health care (hhc). With operations in the U.S., Asia, Europe and it's domestic home market of Japan, Eisai employs more than 11,000 people worldwide. About us History 1941: Eisai founded in Japan 1961: Eisai listed on the Tokyo/Osaka stock exchange 1970: Eisai establishes commercial operations in Indonesia 1981: Eisai establishes its North American operation in California 1988: European operations established 1990: Eisai establishes its UK R&D operation, Eisai London Research Laboratories, at University College London 1993: Eisai introduces the corporate philosophy of hhc (human health care) 1997: Aricept® (donepezil hydrochloride), for the treatment of Alzheimer’s disease, first launched (USA) Pariet® (rabeprazole sodium) a proton pump inhibitor (PPI), used in the treatment of gastro-intestinal disorders, first launched (Japan) 2001: First Environmental and Social Report published 2004: European Regional HQ established (London) 2005: Eisai started marketing Zonegran® (zonisamide) in the US, for the adjunctive treatment of partial-onset seizures in adults 2006: Plans announced for a Strategic European Base in UK 2007: Prialt® (ziconotide), for the treatment of severe, chronic pain in patients who require intrathecal (IT) analgesia, launched in Europe Inovelon® (rufinamide) is first launched in Germany, for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) 2009: European Knowledge Centre opens in Hatfield, UK as European centre Eisai in Europe: Milestones Eisai has been operating in Europe for more than 20 years and our products are available throughout the European Economic Area. Eisai is also preparing to enter other European markets. 1988: European operations established 1990: Eisai establishes its UK R&D operation, the London Research Laboratories, at University College, London 1995: Commercial operations begin in the UK 1996: Commercial operations start in France and Germany 1997: Aricept® (donepezil hydrochloride), for the treatment of Alzheimer’s disease, first launched in Europe 1998: Pariet® (rabeprazole sodium), a proton pump inhibitor (PPI) used in the treatment of gastro-intestinal disorders, launched in Europe 2001: Eisai begins commercial operations in Spain 2004: European Regional HQ established in London 2005: Eisai establishes commercial operations in Italy, Switzerland, Sweden, Austria and Ireland Zonegran® (zonisamide), for the adjunctive treatment of partial-onset seizures in adults, launched in Europe 2006: Plans announced for a Strategic European Base in UK Eisai establishes commercial operations in Portugal, Norway and Denmark Prialt® (ziconotide) used for the treatment of severe, chronic pain is first launched in the UK and Germany 2007: Ground breaking ceremony for European Knowledge Centre (EKC) Commercial operations begin in Finland and Hungary Inovelon® (rufinamide), for the treatment of Lennox-Gastaut Syndrome, a form of severe childhood epilepsy, launched in Europe 2008: First Eisai launch of NeuroBloc® (botulinum toxin type B) for cervical dystonia in the UK and Germany 2009: European Knowledge Centre opens in Hatfield, UK as hub of European operations Zebinix (eslicarbazepine acetate) approved in Europe for the adjunctive treatment of partial-onset seizures in adults Eisai subsidiary launched in Austria Eisai subsidiary launched in Austria Zebinix® (eslicarbazepine acetate) launched in Germany, Denmark, Austria and the UK for the adjunctive treatment of partial-onset seizures in adults Eisai opens regional office in Bahrain Eisai files submission to health authorities in Switzerland for eribulin (E7389), novel anti-cancer agent, for the treatment of metastatic and locally advanced breast cancer Eisai and Quintiles enter into a strategic collaboration to develop Eisai's anticancer compounds Eisai opens new manufacturing and process research base in India 2010: Eisai launches 'aboutmemoryproblems.com' website designed to help people recognise the early signs of Alzheimer's disease and provide guidance for seeking help and advice for those who are concerned about someone close to them Zebinix® (eslicarbazepine acetate) launched in Sweden for the adjunctive treatment of partial-onset seizures in adults Eisai submits regulatory applications for investigational anticancer agent eribulin mesylate (E7389) in Japan, the United States and Europe Eisai subsidiary launched in Canada Please click through to our global site, eisai.com, for further background information on Eisai. HomeAboutCareersProductsResearchNewsContact usEisai WorldwideTransparencyTerms & ConditionsPrivacy PolicyOur Use of CookiesSitemap Code Nonpro-UK2086(1) / Date of preparation April 2014 Last updated: 12/10/2014 5:08:51 PM